Development of Probiotic Tablets Using Microparticles: Viability Studies and Stability Studies
Alternative vectors to deliver viable cells of probiotics, to those conferring limited resistance to gastrointestinal conditions, still need to be sought. Therefore the main goal of the study was to develop tablets able to protect entrapped probiotic bacteria from gastric acidity, thus providing an...
Gespeichert in:
Veröffentlicht in: | AAPS PharmSciTech 2013-03, Vol.14 (1), p.121-127 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 127 |
---|---|
container_issue | 1 |
container_start_page | 121 |
container_title | AAPS PharmSciTech |
container_volume | 14 |
creator | e Silva, J. P. Sousa Sousa, Sérgio C. Costa, Paulo Cerdeira, Emília Amaral, Maria H. Lobo, José Sousa Gomes, Ana M. Pintado, Maria M. Rodrigues, Dina Rocha-Santos, Teresa Freitas, Ana C. |
description | Alternative vectors to deliver viable cells of probiotics, to those conferring limited resistance to gastrointestinal conditions, still need to be sought. Therefore the main goal of the study was to develop tablets able to protect entrapped probiotic bacteria from gastric acidity, thus providing an easily manufacturing scale-up dosage form to deliver probiotics to the vicinity of the human colon. Whey protein concentrate microparticles with
Lactobacillus paracasei
L26 were produced by spray-drying and incorporated in tablets with cellulose acetate phthalate and sodium croscarmellose. The viability of
L
.
paracasei
L.26 throughout tableting as well as its gastric resistance and release from the tablets were evaluated. Storage stability of
L
.
paracasei
L26 tablets was also performed by evaluation of viable cells throughout 60 days at 23°C and 33% relative humidity. A decrease of approximately one logarithmic cycle was observed after the acid stage and the release of
L
.
paracasei
L26 from the tablets occurred only after 4 h in the conditions tested. Microencapsulated
L
.
paracasei
L26 in tablets revealed some susceptibility to the storage conditions tested since the number of viable cells decreased 2 log cycles after 60 days of storage. However, the viability of
L
.
paracasei
L26 after 45 days of storage did not reveal significant susceptibility upon exposure to simulated gastrointestinal conditions. The developed probiotic tablets revealed to be potential vectors for delivering viable cells of
L
.
paracasei
L26 and probably other probiotics to persons/patients who might benefit from probiotic therapy. |
doi_str_mv | 10.1208/s12249-012-9898-9 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3581639</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1427005869</sourcerecordid><originalsourceid>FETCH-LOGICAL-c503t-d2cfa01ac3ec0427311db6f079e4d8aa922ba2e704264602fabc1e4961d52a6a3</originalsourceid><addsrcrecordid>eNqNkUtLxTAQhYMovn-AG-nSTTWZtL2NC0F8g6LgY2mYptNrpLe5Jq3gvzeXq6IuxFWGnDMfM3MY2xJ8VwAv94IAyFTKBaSqVGWqFtiqyCVPlZKw-K1eYWshPHMOUii5zFZAgpRQwip7PKZXat10Ql2fuCa58a6yrrcmucOqpT4k98F24-TKGu-m6KPSUthPHixWtrX9W3LbD7WlkGBXx_rX7wZbarANtPnxrrP705O7o_P08vrs4ujwMjU5l31ag2mQCzSSDM9gJIWoq6LhI0VZXSIqgAqBRlErsoJDg5URlKlC1DlggXKdHcy506GaUG3iNh5bPfV2gv5NO7T6p9LZJz12r1rmpSikioCdD4B3LwOFXk9sMNS22JEbghZxKs7zsviHVQoos5znMlrF3BqPF4Kn5msiwfUsQj2PUMcI9SxCPcNvf1_lq-Mzs2iAuSFEqRuT189u8F087x_Ud5vyqMo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1312845053</pqid></control><display><type>article</type><title>Development of Probiotic Tablets Using Microparticles: Viability Studies and Stability Studies</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>e Silva, J. P. Sousa ; Sousa, Sérgio C. ; Costa, Paulo ; Cerdeira, Emília ; Amaral, Maria H. ; Lobo, José Sousa ; Gomes, Ana M. ; Pintado, Maria M. ; Rodrigues, Dina ; Rocha-Santos, Teresa ; Freitas, Ana C.</creator><creatorcontrib>e Silva, J. P. Sousa ; Sousa, Sérgio C. ; Costa, Paulo ; Cerdeira, Emília ; Amaral, Maria H. ; Lobo, José Sousa ; Gomes, Ana M. ; Pintado, Maria M. ; Rodrigues, Dina ; Rocha-Santos, Teresa ; Freitas, Ana C.</creatorcontrib><description>Alternative vectors to deliver viable cells of probiotics, to those conferring limited resistance to gastrointestinal conditions, still need to be sought. Therefore the main goal of the study was to develop tablets able to protect entrapped probiotic bacteria from gastric acidity, thus providing an easily manufacturing scale-up dosage form to deliver probiotics to the vicinity of the human colon. Whey protein concentrate microparticles with
Lactobacillus paracasei
L26 were produced by spray-drying and incorporated in tablets with cellulose acetate phthalate and sodium croscarmellose. The viability of
L
.
paracasei
L.26 throughout tableting as well as its gastric resistance and release from the tablets were evaluated. Storage stability of
L
.
paracasei
L26 tablets was also performed by evaluation of viable cells throughout 60 days at 23°C and 33% relative humidity. A decrease of approximately one logarithmic cycle was observed after the acid stage and the release of
L
.
paracasei
L26 from the tablets occurred only after 4 h in the conditions tested. Microencapsulated
L
.
paracasei
L26 in tablets revealed some susceptibility to the storage conditions tested since the number of viable cells decreased 2 log cycles after 60 days of storage. However, the viability of
L
.
paracasei
L26 after 45 days of storage did not reveal significant susceptibility upon exposure to simulated gastrointestinal conditions. The developed probiotic tablets revealed to be potential vectors for delivering viable cells of
L
.
paracasei
L26 and probably other probiotics to persons/patients who might benefit from probiotic therapy.</description><identifier>ISSN: 1530-9932</identifier><identifier>EISSN: 1530-9932</identifier><identifier>DOI: 10.1208/s12249-012-9898-9</identifier><identifier>PMID: 23233282</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Biochemistry ; Biomedical and Life Sciences ; Biomedicine ; Biotechnology ; Lactobacillus ; Lactobacillus paracasei ; Pharmacology/Toxicology ; Pharmacy ; Probiotics ; Research Article ; Tablets</subject><ispartof>AAPS PharmSciTech, 2013-03, Vol.14 (1), p.121-127</ispartof><rights>American Association of Pharmaceutical Scientists 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c503t-d2cfa01ac3ec0427311db6f079e4d8aa922ba2e704264602fabc1e4961d52a6a3</citedby><cites>FETCH-LOGICAL-c503t-d2cfa01ac3ec0427311db6f079e4d8aa922ba2e704264602fabc1e4961d52a6a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581639/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581639/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23233282$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>e Silva, J. P. Sousa</creatorcontrib><creatorcontrib>Sousa, Sérgio C.</creatorcontrib><creatorcontrib>Costa, Paulo</creatorcontrib><creatorcontrib>Cerdeira, Emília</creatorcontrib><creatorcontrib>Amaral, Maria H.</creatorcontrib><creatorcontrib>Lobo, José Sousa</creatorcontrib><creatorcontrib>Gomes, Ana M.</creatorcontrib><creatorcontrib>Pintado, Maria M.</creatorcontrib><creatorcontrib>Rodrigues, Dina</creatorcontrib><creatorcontrib>Rocha-Santos, Teresa</creatorcontrib><creatorcontrib>Freitas, Ana C.</creatorcontrib><title>Development of Probiotic Tablets Using Microparticles: Viability Studies and Stability Studies</title><title>AAPS PharmSciTech</title><addtitle>AAPS PharmSciTech</addtitle><addtitle>AAPS PharmSciTech</addtitle><description>Alternative vectors to deliver viable cells of probiotics, to those conferring limited resistance to gastrointestinal conditions, still need to be sought. Therefore the main goal of the study was to develop tablets able to protect entrapped probiotic bacteria from gastric acidity, thus providing an easily manufacturing scale-up dosage form to deliver probiotics to the vicinity of the human colon. Whey protein concentrate microparticles with
Lactobacillus paracasei
L26 were produced by spray-drying and incorporated in tablets with cellulose acetate phthalate and sodium croscarmellose. The viability of
L
.
paracasei
L.26 throughout tableting as well as its gastric resistance and release from the tablets were evaluated. Storage stability of
L
.
paracasei
L26 tablets was also performed by evaluation of viable cells throughout 60 days at 23°C and 33% relative humidity. A decrease of approximately one logarithmic cycle was observed after the acid stage and the release of
L
.
paracasei
L26 from the tablets occurred only after 4 h in the conditions tested. Microencapsulated
L
.
paracasei
L26 in tablets revealed some susceptibility to the storage conditions tested since the number of viable cells decreased 2 log cycles after 60 days of storage. However, the viability of
L
.
paracasei
L26 after 45 days of storage did not reveal significant susceptibility upon exposure to simulated gastrointestinal conditions. The developed probiotic tablets revealed to be potential vectors for delivering viable cells of
L
.
paracasei
L26 and probably other probiotics to persons/patients who might benefit from probiotic therapy.</description><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Lactobacillus</subject><subject>Lactobacillus paracasei</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Probiotics</subject><subject>Research Article</subject><subject>Tablets</subject><issn>1530-9932</issn><issn>1530-9932</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtLxTAQhYMovn-AG-nSTTWZtL2NC0F8g6LgY2mYptNrpLe5Jq3gvzeXq6IuxFWGnDMfM3MY2xJ8VwAv94IAyFTKBaSqVGWqFtiqyCVPlZKw-K1eYWshPHMOUii5zFZAgpRQwip7PKZXat10Ql2fuCa58a6yrrcmucOqpT4k98F24-TKGu-m6KPSUthPHixWtrX9W3LbD7WlkGBXx_rX7wZbarANtPnxrrP705O7o_P08vrs4ujwMjU5l31ag2mQCzSSDM9gJIWoq6LhI0VZXSIqgAqBRlErsoJDg5URlKlC1DlggXKdHcy506GaUG3iNh5bPfV2gv5NO7T6p9LZJz12r1rmpSikioCdD4B3LwOFXk9sMNS22JEbghZxKs7zsviHVQoos5znMlrF3BqPF4Kn5msiwfUsQj2PUMcI9SxCPcNvf1_lq-Mzs2iAuSFEqRuT189u8F087x_Ud5vyqMo</recordid><startdate>20130301</startdate><enddate>20130301</enddate><creator>e Silva, J. P. Sousa</creator><creator>Sousa, Sérgio C.</creator><creator>Costa, Paulo</creator><creator>Cerdeira, Emília</creator><creator>Amaral, Maria H.</creator><creator>Lobo, José Sousa</creator><creator>Gomes, Ana M.</creator><creator>Pintado, Maria M.</creator><creator>Rodrigues, Dina</creator><creator>Rocha-Santos, Teresa</creator><creator>Freitas, Ana C.</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20130301</creationdate><title>Development of Probiotic Tablets Using Microparticles: Viability Studies and Stability Studies</title><author>e Silva, J. P. Sousa ; Sousa, Sérgio C. ; Costa, Paulo ; Cerdeira, Emília ; Amaral, Maria H. ; Lobo, José Sousa ; Gomes, Ana M. ; Pintado, Maria M. ; Rodrigues, Dina ; Rocha-Santos, Teresa ; Freitas, Ana C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c503t-d2cfa01ac3ec0427311db6f079e4d8aa922ba2e704264602fabc1e4961d52a6a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Lactobacillus</topic><topic>Lactobacillus paracasei</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Probiotics</topic><topic>Research Article</topic><topic>Tablets</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>e Silva, J. P. Sousa</creatorcontrib><creatorcontrib>Sousa, Sérgio C.</creatorcontrib><creatorcontrib>Costa, Paulo</creatorcontrib><creatorcontrib>Cerdeira, Emília</creatorcontrib><creatorcontrib>Amaral, Maria H.</creatorcontrib><creatorcontrib>Lobo, José Sousa</creatorcontrib><creatorcontrib>Gomes, Ana M.</creatorcontrib><creatorcontrib>Pintado, Maria M.</creatorcontrib><creatorcontrib>Rodrigues, Dina</creatorcontrib><creatorcontrib>Rocha-Santos, Teresa</creatorcontrib><creatorcontrib>Freitas, Ana C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>AAPS PharmSciTech</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>e Silva, J. P. Sousa</au><au>Sousa, Sérgio C.</au><au>Costa, Paulo</au><au>Cerdeira, Emília</au><au>Amaral, Maria H.</au><au>Lobo, José Sousa</au><au>Gomes, Ana M.</au><au>Pintado, Maria M.</au><au>Rodrigues, Dina</au><au>Rocha-Santos, Teresa</au><au>Freitas, Ana C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of Probiotic Tablets Using Microparticles: Viability Studies and Stability Studies</atitle><jtitle>AAPS PharmSciTech</jtitle><stitle>AAPS PharmSciTech</stitle><addtitle>AAPS PharmSciTech</addtitle><date>2013-03-01</date><risdate>2013</risdate><volume>14</volume><issue>1</issue><spage>121</spage><epage>127</epage><pages>121-127</pages><issn>1530-9932</issn><eissn>1530-9932</eissn><abstract>Alternative vectors to deliver viable cells of probiotics, to those conferring limited resistance to gastrointestinal conditions, still need to be sought. Therefore the main goal of the study was to develop tablets able to protect entrapped probiotic bacteria from gastric acidity, thus providing an easily manufacturing scale-up dosage form to deliver probiotics to the vicinity of the human colon. Whey protein concentrate microparticles with
Lactobacillus paracasei
L26 were produced by spray-drying and incorporated in tablets with cellulose acetate phthalate and sodium croscarmellose. The viability of
L
.
paracasei
L.26 throughout tableting as well as its gastric resistance and release from the tablets were evaluated. Storage stability of
L
.
paracasei
L26 tablets was also performed by evaluation of viable cells throughout 60 days at 23°C and 33% relative humidity. A decrease of approximately one logarithmic cycle was observed after the acid stage and the release of
L
.
paracasei
L26 from the tablets occurred only after 4 h in the conditions tested. Microencapsulated
L
.
paracasei
L26 in tablets revealed some susceptibility to the storage conditions tested since the number of viable cells decreased 2 log cycles after 60 days of storage. However, the viability of
L
.
paracasei
L26 after 45 days of storage did not reveal significant susceptibility upon exposure to simulated gastrointestinal conditions. The developed probiotic tablets revealed to be potential vectors for delivering viable cells of
L
.
paracasei
L26 and probably other probiotics to persons/patients who might benefit from probiotic therapy.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>23233282</pmid><doi>10.1208/s12249-012-9898-9</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1530-9932 |
ispartof | AAPS PharmSciTech, 2013-03, Vol.14 (1), p.121-127 |
issn | 1530-9932 1530-9932 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3581639 |
source | MEDLINE; Springer Nature - Complete Springer Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
subjects | Biochemistry Biomedical and Life Sciences Biomedicine Biotechnology Lactobacillus Lactobacillus paracasei Pharmacology/Toxicology Pharmacy Probiotics Research Article Tablets |
title | Development of Probiotic Tablets Using Microparticles: Viability Studies and Stability Studies |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T00%3A55%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20Probiotic%20Tablets%20Using%20Microparticles:%20Viability%20Studies%20and%20Stability%20Studies&rft.jtitle=AAPS%20PharmSciTech&rft.au=e%20Silva,%20J.%20P.%20Sousa&rft.date=2013-03-01&rft.volume=14&rft.issue=1&rft.spage=121&rft.epage=127&rft.pages=121-127&rft.issn=1530-9932&rft.eissn=1530-9932&rft_id=info:doi/10.1208/s12249-012-9898-9&rft_dat=%3Cproquest_pubme%3E1427005869%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1312845053&rft_id=info:pmid/23233282&rfr_iscdi=true |